WGU D116: ADVANCED PHARMACOLOGY
OA PRACTICE EXAM 2026–2027
(70 Original Practice Questions with Correct Answers & Rationales)
Nursing | Advanced Pharmacology Practice
Key Domains: Pharmacokinetics & Pharmacodynamics • Autonomic Nervous System • Cardiovascular Agents •
Antimicrobials • Analgesics & CNS Drugs • Endocrine Agents • Safe Medication Administration
IMPORTANT DISCLAIMER: This is an ORIGINAL educational practice resource for study purposes only. It is NOT an official
Western Governors University (WGU) Objective Assessment, does NOT contain proprietary WGU OA items or secure assessment
content, and is NOT affiliated with, endorsed by, or produced by WGU. Content is aligned with common advanced nursing
pharmacology themes (ADME, receptor pharmacology, major drug classes, adverse effects, interactions, and safety). Course
competencies, drug lists, and OA blueprints change—always follow your current D116 course of study, learning resources, and
faculty guidance. Drug information must be verified against current drug references and clinical guidelines before practice. This
resource is for independent practice and concept reinforcement only.
Introduction
This structured 70-question practice OA emphasizes pharmacological principles, drug class prototypes,
mechanisms, adverse effects, interactions, and safe administration. Correct answers appear in bold cyan with
concise rationales explaining clinical/safety reasoning. Use this after completing your course materials and
cohort learning—not as a substitute for official WGU assessments or required learning resources.
Suggested Study Use
• Attempt all 70 under timed conditions (~90 minutes) before checking answers.
• For each miss, write: class → prototype → MOA → top 3 AEs/interactions → nursing implications.
• Build comparison tables (ACEI vs ARB, heparin vs warfarin, SABA vs ICS, SSRI vs MAOI).
• Practice teaching points out loud as if discharging a patient.
EXAM QUESTIONS (1–70)
Total: 70 original multiple-choice items. Correct answers in bold cyan with rationales.
PART A — Pharmacokinetics & Pharmacodynamics (Q1–10)
1. Pharmacokinetics is best defined as:
A. What the drug does to the body (receptor effects only)
B. Only the cost of the medication
C. Only the brand name of the drug
D. What the body does to the drug (absorption, distribution, metabolism, excretion)
Correct Answer: D. What the body does to the drug (absorption, distribution, metabolism, excretion)
Rationale: ADME processes describe pharmacokinetics. Pharmacodynamics describes drug effects on the body
(mechanism, potency, efficacy).
2. The first-pass effect primarily refers to:
A. Hepatic metabolism of an orally administered drug before it reaches systemic circulation
B. Protein binding in plasma only
C. Absorption through the skin only
D. Renal excretion of unchanged drug only
Correct Answer: A. Hepatic metabolism of an orally administered drug before it reaches systemic
circulation
, Rationale: Oral drugs absorbed via the GI tract pass through the portal circulation to the liver, reducing bioavailability
for some agents. IV administration bypasses first-pass.
3. Bioavailability is:
A. The fraction of an administered dose that reaches systemic circulation unchanged
B. The time to peak adverse effects only
C. Identical to half-life
D. Always 100% for all oral drugs
Correct Answer: A. The fraction of an administered dose that reaches systemic circulation unchanged
Rationale: IV bioavailability is 100%. Oral bioavailability is reduced by incomplete absorption and first-pass
metabolism.
4. Drug half-life (t½) is the time required for:
A. Peak concentration after a single oral dose only as definition
B. Plasma drug concentration to decrease by 50%
C. Onset of therapeutic effect in all cases
D. Complete elimination of every drug molecule after one half-life
Correct Answer: B. Plasma drug concentration to decrease by 50%
Rationale: After ~4–5 half-lives, a drug is largely eliminated (or steady state is approached with regular dosing). Half-
life guides dosing interval.
5. Steady state is typically approached after approximately:
A. 4 to 5 half-lives of consistent dosing
B. 1 half-life only
C. One single loading dose without maintenance
D. 30 minutes for all drugs
Correct Answer: A. 4 to 5 half-lives of consistent dosing
Rationale: With repeated dosing at a fixed interval, accumulation continues until input equals elimination—about 4–5
half-lives to near steady state.
6. A loading dose is used to:
A. Replace all maintenance dosing forever
B. Avoid all monitoring
C. Rapidly achieve therapeutic concentrations for drugs with long half-lives or when immediate
effect is needed
D. Eliminate renal clearance
Correct Answer: C. Rapidly achieve therapeutic concentrations for drugs with long half-lives or when
immediate effect is needed
Rationale: Loading dose fills the volume of distribution quickly; maintenance doses replace drug lost each interval.
7. Highly protein-bound drugs may have increased free (active) fraction when:
A. Half-life becomes infinite
B. The patient drinks more water only always without binding change
C. Another highly bound drug displaces them or hypoalbuminemia reduces binding sites
D. The drug is given IM instead of IV only as the sole factor
Correct Answer: C. Another highly bound drug displaces them or hypoalbuminemia reduces binding
sites
Rationale: Free drug exerts effect/toxicity. Displacement interactions and low albumin matter for narrow-therapeutic-
index drugs (e.g., warfarin, phenytoin—context dependent).
, 8. Agonists are drugs that:
A. Only increase renal excretion of other drugs
B. Never interact with receptors
C. Bind receptors and activate them to produce a response
D. Bind receptors only to block agonists without any activation (pure antagonists)
Correct Answer: C. Bind receptors and activate them to produce a response
Rationale: Full agonists produce maximal activation; partial agonists produce submaximal activation and can
antagonize full agonists in some settings. Antagonists block activation.
9. A narrow therapeutic index means:
A. The drug is always safe at any dose
B. The drug cannot be effective
C. There is a small margin between therapeutic and toxic plasma concentrations—monitoring and
careful dosing are critical
D. No adverse effects are possible
Correct Answer: C. There is a small margin between therapeutic and toxic plasma concentrations—
monitoring and careful dosing are critical
Rationale: Examples often discussed: warfarin, digoxin, lithium, phenytoin, aminoglycosides, vancomycin—know
monitoring parameters.
10. CYP450 enzyme induction typically causes:
A. No change in drug concentrations ever
B. Complete blockade of renal elimination only
C. Increased metabolism of substrate drugs, potentially lowering their levels/effects
D. Universal increase in all drug levels
Correct Answer: C. Increased metabolism of substrate drugs, potentially lowering their levels/effects
Rationale: Inducers (e.g., rifampin, carbamazepine, St. John's wort—classic teaching examples) can reduce efficacy of
substrates. Inhibitors raise substrate levels and toxicity risk.
PART B — Autonomic Nervous System Pharmacology (Q11–18)
11. Stimulation of beta-1 adrenergic receptors primarily causes:
A. Bronchoconstriction only
B. Miosis and salivation only
C. Decreased aqueous humor production as the only effect
D. Increased heart rate and myocardial contractility
Correct Answer: D. Increased heart rate and myocardial contractility
Rationale: β1: heart (chronotropy/inotropy) and renin release. β2: bronchodilation, vasodilation in some beds, uterine
relaxation. α1: vasoconstriction, mydriasis.
12. A nonselective beta blocker (e.g., propranolol) is relatively contraindicated in clients with:
A. Migraine prophylaxis needs only as absolute contraindication in all cases
B. Performance anxiety as the only concern
C. Essential tremor as the only absolute contraindication
D. Asthma/COPD with reactive airway disease, because β2 blockade can cause bronchoconstriction
Correct Answer: D. Asthma/COPD with reactive airway disease, because β2 blockade can cause
bronchoconstriction
OA PRACTICE EXAM 2026–2027
(70 Original Practice Questions with Correct Answers & Rationales)
Nursing | Advanced Pharmacology Practice
Key Domains: Pharmacokinetics & Pharmacodynamics • Autonomic Nervous System • Cardiovascular Agents •
Antimicrobials • Analgesics & CNS Drugs • Endocrine Agents • Safe Medication Administration
IMPORTANT DISCLAIMER: This is an ORIGINAL educational practice resource for study purposes only. It is NOT an official
Western Governors University (WGU) Objective Assessment, does NOT contain proprietary WGU OA items or secure assessment
content, and is NOT affiliated with, endorsed by, or produced by WGU. Content is aligned with common advanced nursing
pharmacology themes (ADME, receptor pharmacology, major drug classes, adverse effects, interactions, and safety). Course
competencies, drug lists, and OA blueprints change—always follow your current D116 course of study, learning resources, and
faculty guidance. Drug information must be verified against current drug references and clinical guidelines before practice. This
resource is for independent practice and concept reinforcement only.
Introduction
This structured 70-question practice OA emphasizes pharmacological principles, drug class prototypes,
mechanisms, adverse effects, interactions, and safe administration. Correct answers appear in bold cyan with
concise rationales explaining clinical/safety reasoning. Use this after completing your course materials and
cohort learning—not as a substitute for official WGU assessments or required learning resources.
Suggested Study Use
• Attempt all 70 under timed conditions (~90 minutes) before checking answers.
• For each miss, write: class → prototype → MOA → top 3 AEs/interactions → nursing implications.
• Build comparison tables (ACEI vs ARB, heparin vs warfarin, SABA vs ICS, SSRI vs MAOI).
• Practice teaching points out loud as if discharging a patient.
EXAM QUESTIONS (1–70)
Total: 70 original multiple-choice items. Correct answers in bold cyan with rationales.
PART A — Pharmacokinetics & Pharmacodynamics (Q1–10)
1. Pharmacokinetics is best defined as:
A. What the drug does to the body (receptor effects only)
B. Only the cost of the medication
C. Only the brand name of the drug
D. What the body does to the drug (absorption, distribution, metabolism, excretion)
Correct Answer: D. What the body does to the drug (absorption, distribution, metabolism, excretion)
Rationale: ADME processes describe pharmacokinetics. Pharmacodynamics describes drug effects on the body
(mechanism, potency, efficacy).
2. The first-pass effect primarily refers to:
A. Hepatic metabolism of an orally administered drug before it reaches systemic circulation
B. Protein binding in plasma only
C. Absorption through the skin only
D. Renal excretion of unchanged drug only
Correct Answer: A. Hepatic metabolism of an orally administered drug before it reaches systemic
circulation
, Rationale: Oral drugs absorbed via the GI tract pass through the portal circulation to the liver, reducing bioavailability
for some agents. IV administration bypasses first-pass.
3. Bioavailability is:
A. The fraction of an administered dose that reaches systemic circulation unchanged
B. The time to peak adverse effects only
C. Identical to half-life
D. Always 100% for all oral drugs
Correct Answer: A. The fraction of an administered dose that reaches systemic circulation unchanged
Rationale: IV bioavailability is 100%. Oral bioavailability is reduced by incomplete absorption and first-pass
metabolism.
4. Drug half-life (t½) is the time required for:
A. Peak concentration after a single oral dose only as definition
B. Plasma drug concentration to decrease by 50%
C. Onset of therapeutic effect in all cases
D. Complete elimination of every drug molecule after one half-life
Correct Answer: B. Plasma drug concentration to decrease by 50%
Rationale: After ~4–5 half-lives, a drug is largely eliminated (or steady state is approached with regular dosing). Half-
life guides dosing interval.
5. Steady state is typically approached after approximately:
A. 4 to 5 half-lives of consistent dosing
B. 1 half-life only
C. One single loading dose without maintenance
D. 30 minutes for all drugs
Correct Answer: A. 4 to 5 half-lives of consistent dosing
Rationale: With repeated dosing at a fixed interval, accumulation continues until input equals elimination—about 4–5
half-lives to near steady state.
6. A loading dose is used to:
A. Replace all maintenance dosing forever
B. Avoid all monitoring
C. Rapidly achieve therapeutic concentrations for drugs with long half-lives or when immediate
effect is needed
D. Eliminate renal clearance
Correct Answer: C. Rapidly achieve therapeutic concentrations for drugs with long half-lives or when
immediate effect is needed
Rationale: Loading dose fills the volume of distribution quickly; maintenance doses replace drug lost each interval.
7. Highly protein-bound drugs may have increased free (active) fraction when:
A. Half-life becomes infinite
B. The patient drinks more water only always without binding change
C. Another highly bound drug displaces them or hypoalbuminemia reduces binding sites
D. The drug is given IM instead of IV only as the sole factor
Correct Answer: C. Another highly bound drug displaces them or hypoalbuminemia reduces binding
sites
Rationale: Free drug exerts effect/toxicity. Displacement interactions and low albumin matter for narrow-therapeutic-
index drugs (e.g., warfarin, phenytoin—context dependent).
, 8. Agonists are drugs that:
A. Only increase renal excretion of other drugs
B. Never interact with receptors
C. Bind receptors and activate them to produce a response
D. Bind receptors only to block agonists without any activation (pure antagonists)
Correct Answer: C. Bind receptors and activate them to produce a response
Rationale: Full agonists produce maximal activation; partial agonists produce submaximal activation and can
antagonize full agonists in some settings. Antagonists block activation.
9. A narrow therapeutic index means:
A. The drug is always safe at any dose
B. The drug cannot be effective
C. There is a small margin between therapeutic and toxic plasma concentrations—monitoring and
careful dosing are critical
D. No adverse effects are possible
Correct Answer: C. There is a small margin between therapeutic and toxic plasma concentrations—
monitoring and careful dosing are critical
Rationale: Examples often discussed: warfarin, digoxin, lithium, phenytoin, aminoglycosides, vancomycin—know
monitoring parameters.
10. CYP450 enzyme induction typically causes:
A. No change in drug concentrations ever
B. Complete blockade of renal elimination only
C. Increased metabolism of substrate drugs, potentially lowering their levels/effects
D. Universal increase in all drug levels
Correct Answer: C. Increased metabolism of substrate drugs, potentially lowering their levels/effects
Rationale: Inducers (e.g., rifampin, carbamazepine, St. John's wort—classic teaching examples) can reduce efficacy of
substrates. Inhibitors raise substrate levels and toxicity risk.
PART B — Autonomic Nervous System Pharmacology (Q11–18)
11. Stimulation of beta-1 adrenergic receptors primarily causes:
A. Bronchoconstriction only
B. Miosis and salivation only
C. Decreased aqueous humor production as the only effect
D. Increased heart rate and myocardial contractility
Correct Answer: D. Increased heart rate and myocardial contractility
Rationale: β1: heart (chronotropy/inotropy) and renin release. β2: bronchodilation, vasodilation in some beds, uterine
relaxation. α1: vasoconstriction, mydriasis.
12. A nonselective beta blocker (e.g., propranolol) is relatively contraindicated in clients with:
A. Migraine prophylaxis needs only as absolute contraindication in all cases
B. Performance anxiety as the only concern
C. Essential tremor as the only absolute contraindication
D. Asthma/COPD with reactive airway disease, because β2 blockade can cause bronchoconstriction
Correct Answer: D. Asthma/COPD with reactive airway disease, because β2 blockade can cause
bronchoconstriction
